RB

Rahana Beevi Kabeer Kummankandath

Active Director Director DIN 10513146
DIN 10513146 First appointment Feb 2024 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Rahana Beevi Kabeer Kummankandath

Data last updated:

Rahana Beevi Kabeer Kummankandath is a Director at Ryne Bio Life Sciences Private Limited (since 2024). The company operates in Pharma.

DIN 10513146
Primary Designation Director
Industry Pharma
First Appointment 18 Feb 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director18 Feb 20242024Active

Board colleagues of Rahana Beevi Kabeer Kummankandath

Directorship timeline

Open interactive timeline →
Ryne Bio Life Sciences Private Limited
Premium access

Shareholding and investment profile for Rahana Beevi Kabeer Kummankandath

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rahana Beevi Kabeer Kummankandath

Rahana Beevi Kabeer Kummankandath currently holds 1 directorship: Ryne Bio Life Sciences Private Limited (Director, since 18 Feb 2024).

Rahana Beevi Kabeer Kummankandath was first appointed on 18 Feb 2024 as Director at Ryne Bio Life Sciences Private Limited.

The current boards of Rahana Beevi Kabeer Kummankandath's companies include Kadukapeedikayil Kochumon Shajahan (Ryne Bio Life Sciences Private Limited), Umaiba (Ryne Bio Life Sciences Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available